HyQure and CellVoyant Announce Strategic Partnership to Advance AI-Driven Biologics Testing and Quality Control

Collaboration will combine HyQure's expertise in biologics quality control and analytical services with CellVoyant's AI-powered label-free cell analytics to develop next-generation data-driven quality assessment solutions

SHANGHAI/ZHEJIANG, CHINA and BASEL, SWITZERLAND and BRISTOL, UK - 15 July 2026 - HyQure, a leading global CRO specialising in viral safety testing, biologics quality control and advanced analytical services, and CellVoyant, a pioneer in AI foundation models for live-cell analytics and predictive cell biology, today announced a strategic partnership to explore the application of artificial intelligence in biologics testing and quality assessment.

The collaboration brings together HyQure's extensive experience in biologics testing and analytical services with CellVoyant's expertise in AI-powered, label-free cell analysis. Together, the companies aim to develop innovative approaches that enhance the efficiency, consistency, and scalability of quality control workflows across the biopharmaceutical industry.

Through the partnership, the companies will collaborate on the development and validation of AI-enabled analytical solutions designed to support biologics testing and cell characterisation. The collaboration will also establish a foundation for future innovation opportunities in advanced cell analytics and quality assessment technologies.

"HyQure is committed to bringing innovative technologies to our clients," said Shirley Zhu, CEO of HyQure. "This partnership with CellVoyant provides an exciting opportunity to explore how advanced AI can support the future of biologics testing and quality control, ultimately delivering more predictive, scalable and standardised analytical approaches to the industry."

"Biologics development increasingly relies on high-quality, data-driven decision making," said Rafael E. Carazo Salas, Founder and CEO of CellVoyant. "By combining our AI capabilities with HyQure's deep expertise in biologics testing, we aim to accelerate the adoption of more predictive, scalable and standardised analytical approaches across the industry."

The companies also plan to collaborate on joint scientific and commercial activities to promote the adoption of AI-enabled analytics within the biopharmaceutical sector.

By combining complementary expertise in artificial intelligence and biologics testing, HyQure and CellVoyant aim to help advance the next generation of data-driven quality control solutions for biologics and advanced therapies.

HyQure is a global CRO specialising in viral safety testing, biologics quality control and advanced analytical services for the biopharmaceutical industry, supporting clients across biologics, vaccine, and cell and gene therapy development programmes.

CellVoyant has pioneered AI foundation models enabling non-destructive, real-time cell analysis, prediction and optimisation across cell-based therapeutics development, manufacturing workflows and advanced life sciences applications.

HyQure:service@hyqure.com

CellVoyant:info@cellvoyant.com